| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Polycystic Kidney, Autosomal Dominant | 107 | 2023 | 136 | 20.100 |
Why?
|
| Hypertension | 74 | 2024 | 1141 | 6.590 |
Why?
|
| Antihypertensive Agents | 53 | 2024 | 521 | 5.340 |
Why?
|
| Blood Pressure | 59 | 2024 | 1143 | 4.630 |
Why?
|
| Kidney | 53 | 2023 | 1241 | 4.400 |
Why?
|
| Hydrochlorothiazide | 36 | 2024 | 76 | 3.980 |
Why?
|
| Glomerular Filtration Rate | 46 | 2023 | 384 | 3.340 |
Why?
|
| Atenolol | 24 | 2019 | 34 | 2.940 |
Why?
|
| Antidiuretic Hormone Receptor Antagonists | 15 | 2020 | 29 | 2.330 |
Why?
|
| Renal Insufficiency, Chronic | 15 | 2023 | 350 | 2.330 |
Why?
|
| Kidney Failure, Chronic | 19 | 2022 | 509 | 2.220 |
Why?
|
| Disease Progression | 54 | 2023 | 1531 | 2.180 |
Why?
|
| Sodium Chloride Symporter Inhibitors | 14 | 2024 | 43 | 2.100 |
Why?
|
| Polycystic Kidney Diseases | 5 | 2021 | 21 | 2.090 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 11 | 2019 | 90 | 1.990 |
Why?
|
| Benzazepines | 13 | 2018 | 89 | 1.960 |
Why?
|
| Pharmacogenomic Variants | 9 | 2019 | 41 | 1.770 |
Why?
|
| Cysts | 10 | 2023 | 104 | 1.730 |
Why?
|
| Adrenergic beta-Antagonists | 12 | 2019 | 152 | 1.720 |
Why?
|
| Polymorphism, Single Nucleotide | 31 | 2020 | 2357 | 1.710 |
Why?
|
| Pharmacogenetics | 22 | 2022 | 434 | 1.680 |
Why?
|
| Benzimidazoles | 7 | 2019 | 140 | 1.320 |
Why?
|
| Magnetic Resonance Imaging | 34 | 2023 | 3362 | 1.320 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 10 | 2018 | 231 | 1.280 |
Why?
|
| Adult | 126 | 2024 | 25648 | 1.260 |
Why?
|
| Humans | 195 | 2024 | 86645 | 1.260 |
Why?
|
| Male | 147 | 2022 | 40967 | 1.210 |
Why?
|
| Renin-Angiotensin System | 8 | 2018 | 133 | 1.200 |
Why?
|
| Middle Aged | 124 | 2022 | 25028 | 1.200 |
Why?
|
| Female | 146 | 2023 | 44534 | 1.190 |
Why?
|
| Tetrazoles | 5 | 2019 | 50 | 1.170 |
Why?
|
| Renin | 8 | 2020 | 79 | 1.080 |
Why?
|
| Renal Insufficiency | 5 | 2022 | 114 | 0.980 |
Why?
|
| Genome-Wide Association Study | 19 | 2019 | 1621 | 0.950 |
Why?
|
| Adolescent | 56 | 2022 | 8982 | 0.910 |
Why?
|
| Sodium | 4 | 2021 | 341 | 0.900 |
Why?
|
| Chlorthalidone | 7 | 2021 | 25 | 0.900 |
Why?
|
| Pain | 9 | 2021 | 391 | 0.870 |
Why?
|
| Metoprolol | 7 | 2020 | 30 | 0.830 |
Why?
|
| Organ Size | 22 | 2020 | 364 | 0.820 |
Why?
|
| Young Adult | 49 | 2022 | 5976 | 0.800 |
Why?
|
| Biomarkers | 17 | 2024 | 1718 | 0.800 |
Why?
|
| Kidney Calculi | 2 | 2021 | 339 | 0.790 |
Why?
|
| Diuretics | 11 | 2019 | 124 | 0.780 |
Why?
|
| Treatment Outcome | 42 | 2021 | 7993 | 0.770 |
Why?
|
| alpha-Glucosidases | 2 | 2017 | 7 | 0.760 |
Why?
|
| TRPP Cation Channels | 10 | 2020 | 15 | 0.740 |
Why?
|
| Nephrology | 4 | 2020 | 45 | 0.730 |
Why?
|
| Mutation | 13 | 2020 | 3968 | 0.730 |
Why?
|
| Apolipoprotein L1 | 1 | 2019 | 7 | 0.720 |
Why?
|
| Drug Resistance | 2 | 2017 | 256 | 0.700 |
Why?
|
| Prospective Studies | 29 | 2022 | 4213 | 0.690 |
Why?
|
| Adrenergic beta-1 Receptor Antagonists | 4 | 2020 | 9 | 0.660 |
Why?
|
| Retinal Dehydrogenase | 1 | 2017 | 6 | 0.630 |
Why?
|
| Essential Hypertension | 7 | 2019 | 10 | 0.590 |
Why?
|
| Hypertension, Renal | 2 | 2010 | 40 | 0.590 |
Why?
|
| Genotype | 17 | 2020 | 1851 | 0.590 |
Why?
|
| Randomized Controlled Trials as Topic | 12 | 2019 | 865 | 0.550 |
Why?
|
| Severity of Illness Index | 13 | 2018 | 1801 | 0.540 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2016 | 79 | 0.540 |
Why?
|
| Quality of Life | 7 | 2020 | 1585 | 0.540 |
Why?
|
| Receptors, Adrenergic, beta | 1 | 2016 | 72 | 0.540 |
Why?
|
| Angiotensin Receptor Antagonists | 3 | 2018 | 80 | 0.530 |
Why?
|
| Gastrointestinal Diseases | 1 | 2016 | 146 | 0.510 |
Why?
|
| Kidney Diseases | 4 | 2016 | 418 | 0.490 |
Why?
|
| Gastrointestinal Tract | 1 | 2016 | 191 | 0.490 |
Why?
|
| Precision Medicine | 2 | 2019 | 395 | 0.490 |
Why?
|
| Nephritis, Hereditary | 3 | 2022 | 5 | 0.490 |
Why?
|
| Blood Glucose | 8 | 2018 | 873 | 0.460 |
Why?
|
| Creatinine | 9 | 2022 | 338 | 0.450 |
Why?
|
| Multivariate Analysis | 10 | 2021 | 999 | 0.440 |
Why?
|
| Phenotype | 12 | 2020 | 2378 | 0.440 |
Why?
|
| Double-Blind Method | 16 | 2022 | 1823 | 0.440 |
Why?
|
| Disease Management | 2 | 2014 | 327 | 0.420 |
Why?
|
| Oleanolic Acid | 2 | 2022 | 13 | 0.420 |
Why?
|
| Infant, Low Birth Weight | 1 | 2012 | 58 | 0.420 |
Why?
|
| Drug Therapy, Combination | 13 | 2014 | 894 | 0.420 |
Why?
|
| Enalapril | 2 | 2009 | 18 | 0.400 |
Why?
|
| Risk Factors | 19 | 2021 | 5417 | 0.400 |
Why?
|
| Aged | 32 | 2022 | 18415 | 0.400 |
Why?
|
| Risk Assessment | 12 | 2020 | 2262 | 0.400 |
Why?
|
| Time Factors | 18 | 2020 | 5210 | 0.400 |
Why?
|
| Cost of Illness | 3 | 2019 | 150 | 0.390 |
Why?
|
| Hyperglycemia | 5 | 2018 | 176 | 0.390 |
Why?
|
| Liver Diseases | 5 | 2022 | 238 | 0.380 |
Why?
|
| Prognosis | 16 | 2023 | 3680 | 0.370 |
Why?
|
| Predictive Value of Tests | 14 | 2020 | 1673 | 0.350 |
Why?
|
| Sorting Nexins | 2 | 2020 | 4 | 0.350 |
Why?
|
| Linear Models | 10 | 2017 | 421 | 0.340 |
Why?
|
| Biphenyl Compounds | 5 | 2019 | 68 | 0.340 |
Why?
|
| Logistic Models | 8 | 2017 | 1187 | 0.330 |
Why?
|
| Staff Development | 1 | 2008 | 21 | 0.330 |
Why?
|
| Longitudinal Studies | 11 | 2019 | 1019 | 0.330 |
Why?
|
| Calcium Channel Blockers | 3 | 2019 | 203 | 0.330 |
Why?
|
| Genetic Predisposition to Disease | 10 | 2017 | 2271 | 0.330 |
Why?
|
| Faculty, Medical | 2 | 2020 | 178 | 0.330 |
Why?
|
| Tumor Suppressor Proteins | 4 | 2016 | 279 | 0.320 |
Why?
|
| United States | 17 | 2022 | 6674 | 0.320 |
Why?
|
| Heart Rate | 3 | 2020 | 492 | 0.320 |
Why?
|
| Analgesics | 1 | 2009 | 119 | 0.310 |
Why?
|
| Patient Outcome Assessment | 2 | 2019 | 84 | 0.310 |
Why?
|
| Cytochrome P-450 CYP2D6 | 2 | 2020 | 52 | 0.310 |
Why?
|
| Image Processing, Computer-Assisted | 7 | 2020 | 1204 | 0.300 |
Why?
|
| Patient Reported Outcome Measures | 4 | 2021 | 166 | 0.300 |
Why?
|
| Caregivers | 4 | 2020 | 151 | 0.290 |
Why?
|
| Albuminuria | 5 | 2016 | 153 | 0.290 |
Why?
|
| Education, Medical | 2 | 2011 | 233 | 0.290 |
Why?
|
| Odds Ratio | 4 | 2017 | 678 | 0.280 |
Why?
|
| Ultrasonography | 6 | 2015 | 695 | 0.280 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 8 | 2016 | 83 | 0.280 |
Why?
|
| Polymorphism, Genetic | 7 | 2016 | 819 | 0.280 |
Why?
|
| Academic Medical Centers | 1 | 2008 | 379 | 0.270 |
Why?
|
| Kidney Function Tests | 6 | 2020 | 123 | 0.270 |
Why?
|
| Lisinopril | 2 | 2014 | 14 | 0.260 |
Why?
|
| Potassium | 4 | 2021 | 281 | 0.250 |
Why?
|
| Age Factors | 9 | 2018 | 1851 | 0.250 |
Why?
|
| Benzoates | 2 | 2014 | 44 | 0.250 |
Why?
|
| Genetic Association Studies | 5 | 2018 | 294 | 0.250 |
Why?
|
| Biomedical Research | 1 | 2008 | 376 | 0.240 |
Why?
|
| Circulating MicroRNA | 1 | 2024 | 12 | 0.240 |
Why?
|
| Nephrologists | 2 | 2020 | 9 | 0.240 |
Why?
|
| Intracranial Aneurysm | 3 | 2020 | 158 | 0.240 |
Why?
|
| Research Design | 5 | 2021 | 594 | 0.230 |
Why?
|
| Uric Acid | 5 | 2019 | 139 | 0.230 |
Why?
|
| Alanine Transaminase | 2 | 2020 | 73 | 0.230 |
Why?
|
| Chi-Square Distribution | 4 | 2017 | 364 | 0.230 |
Why?
|
| Clinical Trials as Topic | 4 | 2020 | 1169 | 0.230 |
Why?
|
| Gene Expression Profiling | 3 | 2018 | 1384 | 0.230 |
Why?
|
| Consensus | 4 | 2020 | 335 | 0.220 |
Why?
|
| Cystatin C | 1 | 2022 | 31 | 0.210 |
Why?
|
| Medical History Taking | 2 | 2017 | 80 | 0.210 |
Why?
|
| Metabolic Syndrome | 2 | 2015 | 141 | 0.210 |
Why?
|
| Image Interpretation, Computer-Assisted | 3 | 2017 | 663 | 0.210 |
Why?
|
| Metabolic Diseases | 2 | 2021 | 48 | 0.210 |
Why?
|
| Pregnancy Outcome | 1 | 2023 | 247 | 0.210 |
Why?
|
| Aldosterone | 4 | 2015 | 65 | 0.200 |
Why?
|
| Calcium, Dietary | 1 | 2021 | 63 | 0.200 |
Why?
|
| Fasting | 4 | 2015 | 161 | 0.200 |
Why?
|
| Cohort Studies | 9 | 2020 | 2767 | 0.200 |
Why?
|
| Pharmacogenomic Testing | 2 | 2019 | 97 | 0.200 |
Why?
|
| Aspartate Aminotransferases | 1 | 2020 | 73 | 0.190 |
Why?
|
| Receptors, Adrenergic, beta-2 | 2 | 2019 | 36 | 0.190 |
Why?
|
| Calcium Phosphates | 1 | 2021 | 77 | 0.190 |
Why?
|
| Bone Diseases | 1 | 2020 | 54 | 0.190 |
Why?
|
| Child | 6 | 2022 | 6928 | 0.190 |
Why?
|
| Liver | 4 | 2022 | 1230 | 0.190 |
Why?
|
| Verapamil | 2 | 2017 | 48 | 0.180 |
Why?
|
| Metabolomics | 3 | 2017 | 68 | 0.180 |
Why?
|
| Advisory Committees | 1 | 2020 | 90 | 0.180 |
Why?
|
| Georgia | 2 | 2017 | 34 | 0.180 |
Why?
|
| Membrane Proteins | 3 | 2015 | 1196 | 0.180 |
Why?
|
| ADP-ribosyl Cyclase | 1 | 2019 | 6 | 0.180 |
Why?
|
| Chromosomes, Human, Pair 2 | 1 | 2019 | 85 | 0.180 |
Why?
|
| Gastric Bypass | 1 | 2021 | 110 | 0.180 |
Why?
|
| Calcium Oxalate | 1 | 2021 | 185 | 0.180 |
Why?
|
| Models, Biological | 2 | 2019 | 1749 | 0.180 |
Why?
|
| Sequence Analysis, DNA | 3 | 2019 | 853 | 0.180 |
Why?
|
| Reproducibility of Results | 11 | 2019 | 2705 | 0.180 |
Why?
|
| Pregnancy | 2 | 2023 | 2894 | 0.180 |
Why?
|
| Genetic Testing | 2 | 2017 | 535 | 0.170 |
Why?
|
| Glycopeptides | 1 | 2019 | 16 | 0.170 |
Why?
|
| Mortality | 1 | 2020 | 149 | 0.170 |
Why?
|
| Fellowships and Scholarships | 1 | 2020 | 108 | 0.170 |
Why?
|
| Indoles | 2 | 2019 | 318 | 0.170 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2022 | 1373 | 0.170 |
Why?
|
| Genetic Markers | 2 | 2017 | 476 | 0.170 |
Why?
|
| Gadolinium | 2 | 2010 | 103 | 0.170 |
Why?
|
| Bestrophins | 1 | 2018 | 1 | 0.170 |
Why?
|
| Genotyping Techniques | 2 | 2019 | 68 | 0.170 |
Why?
|
| Iothalamic Acid | 3 | 2015 | 11 | 0.160 |
Why?
|
| Hydroxymethylglutaryl-CoA Synthase | 1 | 2018 | 3 | 0.160 |
Why?
|
| Obesity | 2 | 2017 | 963 | 0.160 |
Why?
|
| Angiopoietin-2 | 1 | 2018 | 15 | 0.160 |
Why?
|
| Sex Factors | 5 | 2021 | 1054 | 0.160 |
Why?
|
| Life Style | 1 | 2019 | 189 | 0.160 |
Why?
|
| Emotional Adjustment | 1 | 2017 | 2 | 0.160 |
Why?
|
| Sphingolipids | 1 | 2017 | 20 | 0.160 |
Why?
|
| Caffeine | 1 | 2018 | 81 | 0.160 |
Why?
|
| Muscle Proteins | 1 | 2018 | 132 | 0.160 |
Why?
|
| Florida | 1 | 2017 | 55 | 0.160 |
Why?
|
| Endpoint Determination | 1 | 2017 | 60 | 0.160 |
Why?
|
| Blood Pressure Determination | 3 | 2016 | 90 | 0.150 |
Why?
|
| Age of Onset | 2 | 2012 | 310 | 0.150 |
Why?
|
| Cardiovascular Diseases | 3 | 2020 | 827 | 0.150 |
Why?
|
| DNA Mutational Analysis | 2 | 2017 | 526 | 0.150 |
Why?
|
| Receptors, Odorant | 1 | 2018 | 37 | 0.150 |
Why?
|
| Antigens, CD | 1 | 2019 | 458 | 0.150 |
Why?
|
| Follow-Up Studies | 9 | 2017 | 3640 | 0.150 |
Why?
|
| Regression Analysis | 6 | 2013 | 596 | 0.150 |
Why?
|
| Chemokine CCL2 | 1 | 2017 | 47 | 0.150 |
Why?
|
| Drug Combinations | 1 | 2017 | 224 | 0.150 |
Why?
|
| Diet, Sodium-Restricted | 1 | 2016 | 14 | 0.150 |
Why?
|
| Sodium Chloride, Dietary | 1 | 2016 | 11 | 0.150 |
Why?
|
| Oxidative Stress | 1 | 2020 | 447 | 0.150 |
Why?
|
| Early Diagnosis | 2 | 2008 | 131 | 0.150 |
Why?
|
| Vasodilator Agents | 1 | 2017 | 152 | 0.150 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2018 | 151 | 0.150 |
Why?
|
| Time-to-Treatment | 1 | 2018 | 98 | 0.150 |
Why?
|
| Fibroblast Growth Factors | 1 | 2017 | 80 | 0.150 |
Why?
|
| Patient Selection | 4 | 2019 | 686 | 0.150 |
Why?
|
| Fatigue | 1 | 2017 | 174 | 0.150 |
Why?
|
| Epoxide Hydrolases | 1 | 2016 | 7 | 0.140 |
Why?
|
| Societies, Medical | 1 | 2020 | 572 | 0.140 |
Why?
|
| Pain Management | 1 | 2017 | 127 | 0.140 |
Why?
|
| Databases, Factual | 2 | 2021 | 814 | 0.140 |
Why?
|
| Genetic Loci | 2 | 2019 | 250 | 0.140 |
Why?
|
| Receptor-Like Protein Tyrosine Phosphatases, Class 2 | 1 | 2015 | 2 | 0.140 |
Why?
|
| Abdomen | 1 | 2016 | 122 | 0.140 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2016 | 64 | 0.140 |
Why?
|
| Cholesterol, HDL | 2 | 2013 | 165 | 0.130 |
Why?
|
| Dose-Response Relationship, Drug | 5 | 2017 | 1961 | 0.130 |
Why?
|
| Kidney Transplantation | 1 | 2022 | 849 | 0.130 |
Why?
|
| Amino Acids, Aromatic | 1 | 2015 | 3 | 0.130 |
Why?
|
| Delphi Technique | 3 | 2020 | 80 | 0.130 |
Why?
|
| Amino Acids, Branched-Chain | 1 | 2015 | 7 | 0.130 |
Why?
|
| Renal Circulation | 2 | 2006 | 61 | 0.130 |
Why?
|
| Plasma Membrane Calcium-Transporting ATPases | 1 | 2014 | 5 | 0.130 |
Why?
|
| Heart Ventricles | 2 | 2011 | 760 | 0.130 |
Why?
|
| Receptors, Cell Surface | 1 | 2016 | 286 | 0.130 |
Why?
|
| Hepatomegaly | 1 | 2014 | 15 | 0.130 |
Why?
|
| ROC Curve | 4 | 2020 | 752 | 0.130 |
Why?
|
| Personnel Selection | 2 | 2020 | 59 | 0.130 |
Why?
|
| Body Height | 3 | 2020 | 99 | 0.120 |
Why?
|
| Multicenter Studies as Topic | 2 | 2017 | 159 | 0.120 |
Why?
|
| Patient Safety | 1 | 2017 | 212 | 0.120 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2015 | 645 | 0.120 |
Why?
|
| MicroRNAs | 1 | 2019 | 534 | 0.120 |
Why?
|
| Vascular Stiffness | 1 | 2014 | 26 | 0.120 |
Why?
|
| Arterial Pressure | 1 | 2014 | 38 | 0.120 |
Why?
|
| Combined Modality Therapy | 1 | 2017 | 1686 | 0.120 |
Why?
|
| Gene Rearrangement | 2 | 2018 | 170 | 0.120 |
Why?
|
| Peptides | 1 | 2017 | 639 | 0.120 |
Why?
|
| Endosomal Sorting Complexes Required for Transport | 1 | 2013 | 15 | 0.110 |
Why?
|
| Body Mass Index | 3 | 2017 | 770 | 0.110 |
Why?
|
| Fructokinases | 1 | 2013 | 1 | 0.110 |
Why?
|
| Glucose Transporter Type 5 | 1 | 2013 | 6 | 0.110 |
Why?
|
| Glucose Transporter Type 2 | 1 | 2013 | 10 | 0.110 |
Why?
|
| Contrast Media | 4 | 2015 | 1078 | 0.110 |
Why?
|
| Linkage Disequilibrium | 4 | 2019 | 473 | 0.110 |
Why?
|
| Amino Acids | 1 | 2014 | 252 | 0.110 |
Why?
|
| Administration, Oral | 2 | 2020 | 684 | 0.110 |
Why?
|
| Hypertrophy, Left Ventricular | 2 | 2011 | 73 | 0.110 |
Why?
|
| G-Protein-Coupled Receptor Kinase 4 | 1 | 2012 | 2 | 0.110 |
Why?
|
| Hypoxia | 1 | 2018 | 641 | 0.110 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2017 | 378 | 0.110 |
Why?
|
| Metabolome | 1 | 2013 | 47 | 0.110 |
Why?
|
| Organic Cation Transport Proteins | 1 | 2012 | 13 | 0.110 |
Why?
|
| Organic Anion Transporters | 1 | 2012 | 27 | 0.110 |
Why?
|
| Aorta | 1 | 2014 | 280 | 0.110 |
Why?
|
| Transcriptome | 1 | 2017 | 580 | 0.110 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2013 | 165 | 0.100 |
Why?
|
| Algorithms | 2 | 2018 | 1830 | 0.100 |
Why?
|
| Urinalysis | 3 | 2021 | 33 | 0.100 |
Why?
|
| Proteome | 1 | 2013 | 124 | 0.100 |
Why?
|
| Hormone Antagonists | 1 | 2011 | 20 | 0.100 |
Why?
|
| Pain Measurement | 2 | 2013 | 321 | 0.100 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2020 | 2601 | 0.100 |
Why?
|
| Lysine | 1 | 2012 | 147 | 0.100 |
Why?
|
| Health Status | 1 | 2013 | 360 | 0.100 |
Why?
|
| G-Protein-Coupled Receptor Kinase 5 | 1 | 2011 | 4 | 0.100 |
Why?
|
| Proteomics | 1 | 2013 | 212 | 0.100 |
Why?
|
| G-Protein-Coupled Receptor Kinase 2 | 1 | 2011 | 22 | 0.100 |
Why?
|
| Specialization | 1 | 2011 | 65 | 0.100 |
Why?
|
| Circadian Rhythm | 1 | 2013 | 303 | 0.090 |
Why?
|
| Kidney Diseases, Cystic | 1 | 2010 | 23 | 0.090 |
Why?
|
| Lipopolysaccharide Receptors | 1 | 2010 | 23 | 0.090 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 2 | 2010 | 379 | 0.090 |
Why?
|
| Signal Transduction | 3 | 2016 | 3241 | 0.090 |
Why?
|
| Dialysis | 1 | 2010 | 24 | 0.090 |
Why?
|
| Nephrogenic Fibrosing Dermopathy | 1 | 2010 | 9 | 0.090 |
Why?
|
| Hamartoma | 1 | 2010 | 31 | 0.090 |
Why?
|
| Mass Spectrometry | 3 | 2017 | 188 | 0.090 |
Why?
|
| Republic of Korea | 2 | 2020 | 31 | 0.090 |
Why?
|
| France | 2 | 2020 | 47 | 0.090 |
Why?
|
| Molecular Diagnostic Techniques | 2 | 2007 | 69 | 0.090 |
Why?
|
| Obesity, Abdominal | 1 | 2009 | 8 | 0.090 |
Why?
|
| Histones | 1 | 2012 | 311 | 0.090 |
Why?
|
| Australia | 2 | 2020 | 99 | 0.090 |
Why?
|
| Teaching | 1 | 2011 | 147 | 0.090 |
Why?
|
| Kininogens | 1 | 2009 | 6 | 0.090 |
Why?
|
| Hypokalemia | 1 | 2009 | 29 | 0.090 |
Why?
|
| Homeodomain Proteins | 1 | 2013 | 536 | 0.090 |
Why?
|
| Alleles | 3 | 2019 | 1128 | 0.090 |
Why?
|
| Renal Artery | 1 | 2010 | 64 | 0.090 |
Why?
|
| Diagnostic Imaging | 1 | 2013 | 469 | 0.090 |
Why?
|
| Surveys and Questionnaires | 3 | 2017 | 2501 | 0.090 |
Why?
|
| Stakeholder Participation | 2 | 2020 | 19 | 0.090 |
Why?
|
| Body Weight | 2 | 2008 | 459 | 0.090 |
Why?
|
| Amlodipine | 2 | 2015 | 37 | 0.090 |
Why?
|
| DNA-Binding Proteins | 1 | 2015 | 1208 | 0.080 |
Why?
|
| Retrospective Studies | 6 | 2022 | 8491 | 0.080 |
Why?
|
| Focus Groups | 2 | 2020 | 155 | 0.080 |
Why?
|
| Internet | 1 | 2011 | 312 | 0.080 |
Why?
|
| Family Relations | 1 | 2008 | 35 | 0.080 |
Why?
|
| Career Mobility | 1 | 2008 | 31 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 12 | 1 | 2008 | 65 | 0.080 |
Why?
|
| Phantoms, Imaging | 3 | 2010 | 429 | 0.080 |
Why?
|
| Educational Status | 1 | 2009 | 188 | 0.080 |
Why?
|
| Research Support as Topic | 1 | 2008 | 80 | 0.080 |
Why?
|
| Job Satisfaction | 1 | 2008 | 73 | 0.080 |
Why?
|
| Program Development | 1 | 2008 | 124 | 0.080 |
Why?
|
| Forecasting | 2 | 2016 | 304 | 0.080 |
Why?
|
| Practice Guidelines as Topic | 1 | 2015 | 1036 | 0.080 |
Why?
|
| Mentors | 1 | 2008 | 76 | 0.080 |
Why?
|
| Bisoprolol | 2 | 2019 | 3 | 0.080 |
Why?
|
| Cross-Sectional Studies | 3 | 2022 | 1621 | 0.080 |
Why?
|
| Workload | 1 | 2008 | 128 | 0.080 |
Why?
|
| Cooperative Behavior | 1 | 2008 | 174 | 0.080 |
Why?
|
| Meta-Analysis as Topic | 2 | 2019 | 87 | 0.070 |
Why?
|
| Case-Control Studies | 4 | 2015 | 1805 | 0.070 |
Why?
|
| Career Choice | 1 | 2008 | 139 | 0.070 |
Why?
|
| Renal Artery Obstruction | 1 | 2007 | 39 | 0.070 |
Why?
|
| Nitric Oxide Synthase | 2 | 2005 | 125 | 0.070 |
Why?
|
| Incidence | 3 | 2018 | 1577 | 0.070 |
Why?
|
| Clinical Decision-Making | 2 | 2019 | 257 | 0.070 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2010 | 589 | 0.070 |
Why?
|
| Mutation, Missense | 2 | 2019 | 276 | 0.070 |
Why?
|
| Proportional Hazards Models | 2 | 2018 | 859 | 0.070 |
Why?
|
| Gene Frequency | 4 | 2015 | 677 | 0.070 |
Why?
|
| Electrophoresis, Capillary | 2 | 2017 | 12 | 0.070 |
Why?
|
| Area Under Curve | 2 | 2017 | 334 | 0.070 |
Why?
|
| Automation, Laboratory | 2 | 2016 | 10 | 0.070 |
Why?
|
| Metabolic Networks and Pathways | 2 | 2017 | 79 | 0.070 |
Why?
|
| Registries | 1 | 2009 | 703 | 0.070 |
Why?
|
| Losartan | 2 | 2015 | 42 | 0.060 |
Why?
|
| Lipid Metabolism | 2 | 2017 | 196 | 0.060 |
Why?
|
| Natriuresis | 2 | 2016 | 30 | 0.060 |
Why?
|
| Microfilament Proteins | 2 | 2017 | 208 | 0.060 |
Why?
|
| Up-Regulation | 2 | 2017 | 712 | 0.060 |
Why?
|
| Polycystic Kidney, Autosomal Recessive | 1 | 2003 | 2 | 0.060 |
Why?
|
| Thiazides | 1 | 2024 | 19 | 0.060 |
Why?
|
| Fabry Disease | 1 | 2003 | 6 | 0.060 |
Why?
|
| Osmolar Concentration | 2 | 2016 | 181 | 0.060 |
Why?
|
| Risk | 2 | 2017 | 674 | 0.060 |
Why?
|
| Tuberous Sclerosis | 1 | 2003 | 28 | 0.060 |
Why?
|
| Calmodulin-Binding Proteins | 1 | 2003 | 20 | 0.060 |
Why?
|
| Genetic Heterogeneity | 1 | 2003 | 62 | 0.060 |
Why?
|
| Diastole | 2 | 2019 | 144 | 0.060 |
Why?
|
| Basement Membrane | 1 | 2003 | 54 | 0.060 |
Why?
|
| Kidney Glomerulus | 1 | 2003 | 123 | 0.060 |
Why?
|
| Hyperaldosteronism | 1 | 2002 | 13 | 0.060 |
Why?
|
| Peptidyl-Dipeptidase A | 1 | 2002 | 32 | 0.060 |
Why?
|
| Syndrome | 1 | 2003 | 446 | 0.060 |
Why?
|
| Mice | 4 | 2020 | 11352 | 0.050 |
Why?
|
| Genetic Variation | 1 | 2009 | 1351 | 0.050 |
Why?
|
| Demography | 2 | 2013 | 177 | 0.050 |
Why?
|
| Outpatients | 1 | 2022 | 94 | 0.050 |
Why?
|
| Drug Administration Schedule | 2 | 2015 | 916 | 0.050 |
Why?
|
| RNA, Messenger | 2 | 2017 | 1981 | 0.050 |
Why?
|
| Bicarbonates | 1 | 2021 | 60 | 0.050 |
Why?
|
| Systole | 2 | 2015 | 129 | 0.050 |
Why?
|
| Preoperative Period | 1 | 2021 | 91 | 0.050 |
Why?
|
| Pedigree | 2 | 2016 | 966 | 0.050 |
Why?
|
| Parents | 1 | 2003 | 272 | 0.050 |
Why?
|
| Urine | 1 | 2021 | 90 | 0.050 |
Why?
|
| Administrative Personnel | 1 | 2020 | 8 | 0.050 |
Why?
|
| Minerals | 1 | 2020 | 22 | 0.050 |
Why?
|
| Salaries and Fringe Benefits | 1 | 2020 | 23 | 0.050 |
Why?
|
| Pregnancy Complications | 1 | 2003 | 336 | 0.050 |
Why?
|
| Sulfonamides | 1 | 2002 | 300 | 0.050 |
Why?
|
| Receptor, Angiotensin, Type 1 | 1 | 2020 | 21 | 0.050 |
Why?
|
| Lipoproteins, HDL | 2 | 2011 | 96 | 0.050 |
Why?
|
| Efficiency | 1 | 2020 | 40 | 0.050 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2020 | 69 | 0.050 |
Why?
|
| Africa | 1 | 2020 | 98 | 0.050 |
Why?
|
| Asia | 1 | 2020 | 95 | 0.050 |
Why?
|
| Postoperative Period | 1 | 2021 | 303 | 0.050 |
Why?
|
| Genomics | 2 | 2017 | 720 | 0.050 |
Why?
|
| Kidney Tubules, Proximal | 1 | 2020 | 61 | 0.050 |
Why?
|
| Survival Analysis | 1 | 2003 | 1538 | 0.040 |
Why?
|
| Attitude | 1 | 2020 | 127 | 0.040 |
Why?
|
| GPI-Linked Proteins | 1 | 2019 | 50 | 0.040 |
Why?
|
| NADPH Oxidases | 1 | 2020 | 81 | 0.040 |
Why?
|
| Epithelial Sodium Channels | 2 | 2012 | 7 | 0.040 |
Why?
|
| Psychometrics | 1 | 2021 | 327 | 0.040 |
Why?
|
| Self Concept | 1 | 2020 | 133 | 0.040 |
Why?
|
| Heterotrimeric GTP-Binding Proteins | 1 | 2019 | 11 | 0.040 |
Why?
|
| Receptors, Adrenergic, beta-1 | 1 | 2019 | 8 | 0.040 |
Why?
|
| Mosaicism | 1 | 2019 | 67 | 0.040 |
Why?
|
| Observer Variation | 2 | 2013 | 602 | 0.040 |
Why?
|
| Heart | 1 | 2002 | 539 | 0.040 |
Why?
|
| Patients | 1 | 2020 | 100 | 0.040 |
Why?
|
| Activities of Daily Living | 1 | 2020 | 204 | 0.040 |
Why?
|
| Oxidation-Reduction | 1 | 2020 | 373 | 0.040 |
Why?
|
| Image Enhancement | 2 | 2016 | 563 | 0.040 |
Why?
|
| Patient Acuity | 1 | 2019 | 33 | 0.040 |
Why?
|
| Evaluation Studies as Topic | 1 | 2019 | 274 | 0.040 |
Why?
|
| Renal Dialysis | 1 | 2022 | 355 | 0.040 |
Why?
|
| Animals | 5 | 2020 | 26582 | 0.040 |
Why?
|
| Qualitative Research | 1 | 2020 | 256 | 0.040 |
Why?
|
| Sensitivity and Specificity | 3 | 2013 | 1991 | 0.040 |
Why?
|
| Dehydration | 1 | 2018 | 18 | 0.040 |
Why?
|
| Diuresis | 1 | 2018 | 29 | 0.040 |
Why?
|
| Pseudouridine | 1 | 2019 | 19 | 0.040 |
Why?
|
| Observational Studies as Topic | 1 | 2018 | 48 | 0.040 |
Why?
|
| Protein Transport | 1 | 2020 | 411 | 0.040 |
Why?
|
| Angiotensin II | 1 | 2018 | 94 | 0.040 |
Why?
|
| Triglycerides | 2 | 2011 | 232 | 0.040 |
Why?
|
| Serine C-Palmitoyltransferase | 1 | 2017 | 4 | 0.040 |
Why?
|
| RNA, Small Interfering | 1 | 2020 | 547 | 0.040 |
Why?
|
| Siloxanes | 1 | 2017 | 5 | 0.040 |
Why?
|
| CCAAT-Enhancer-Binding Protein-delta | 1 | 2017 | 4 | 0.040 |
Why?
|
| Clinical Protocols | 1 | 2018 | 156 | 0.040 |
Why?
|
| Ethnopharmacology | 1 | 2017 | 2 | 0.040 |
Why?
|
| Health Personnel | 1 | 2020 | 202 | 0.040 |
Why?
|
| Transcription Factors | 2 | 2017 | 1565 | 0.040 |
Why?
|
| Infant, Newborn | 1 | 2003 | 2379 | 0.040 |
Why?
|
| Medication Therapy Management | 1 | 2017 | 16 | 0.040 |
Why?
|
| Healthcare Disparities | 1 | 2022 | 371 | 0.040 |
Why?
|
| Attitude to Health | 1 | 2019 | 220 | 0.040 |
Why?
|
| Socioeconomic Factors | 1 | 2020 | 567 | 0.040 |
Why?
|
| Bilirubin | 1 | 2017 | 125 | 0.040 |
Why?
|
| Nitriles | 1 | 2017 | 149 | 0.040 |
Why?
|
| Reference Values | 2 | 2013 | 674 | 0.040 |
Why?
|
| Reactive Oxygen Species | 1 | 2020 | 480 | 0.040 |
Why?
|
| Half-Life | 1 | 2017 | 96 | 0.040 |
Why?
|
| Renal Elimination | 1 | 2016 | 8 | 0.040 |
Why?
|
| Stress, Psychological | 1 | 2020 | 313 | 0.040 |
Why?
|
| DCC Receptor | 1 | 2016 | 4 | 0.040 |
Why?
|
| Overweight | 1 | 2017 | 118 | 0.040 |
Why?
|
| Patient-Centered Care | 1 | 2019 | 203 | 0.040 |
Why?
|
| Single-Blind Method | 1 | 2016 | 153 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2018 | 860 | 0.040 |
Why?
|
| Hypernatremia | 1 | 2016 | 9 | 0.040 |
Why?
|
| Immunoprecipitation | 1 | 2016 | 134 | 0.030 |
Why?
|
| Bayes Theorem | 1 | 2018 | 361 | 0.030 |
Why?
|
| Cell Adhesion Molecules | 1 | 2017 | 163 | 0.030 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2019 | 456 | 0.030 |
Why?
|
| CRISPR-Cas Systems | 1 | 2016 | 70 | 0.030 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2016 | 316 | 0.030 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2016 | 416 | 0.030 |
Why?
|
| Phosphoproteins | 1 | 2017 | 254 | 0.030 |
Why?
|
| Morbidity | 1 | 2016 | 148 | 0.030 |
Why?
|
| Microscopy, Confocal | 1 | 2016 | 268 | 0.030 |
Why?
|
| Cell Line | 1 | 2020 | 2468 | 0.030 |
Why?
|
| Aldehyde Oxidoreductases | 1 | 2015 | 4 | 0.030 |
Why?
|
| Finland | 1 | 2015 | 29 | 0.030 |
Why?
|
| Italy | 1 | 2015 | 106 | 0.030 |
Why?
|
| Dioxygenases | 1 | 2015 | 74 | 0.030 |
Why?
|
| Puerto Rico | 1 | 2014 | 31 | 0.030 |
Why?
|
| Chloride Channels | 1 | 2015 | 42 | 0.030 |
Why?
|
| Prevalence | 2 | 2011 | 1239 | 0.030 |
Why?
|
| Survival Rate | 1 | 2018 | 1863 | 0.030 |
Why?
|
| Sodium Channels | 2 | 2005 | 129 | 0.030 |
Why?
|
| Chromatography, Liquid | 1 | 2015 | 104 | 0.030 |
Why?
|
| Liver Function Tests | 1 | 2014 | 93 | 0.030 |
Why?
|
| Gene Dosage | 1 | 2015 | 207 | 0.030 |
Why?
|
| Gene Duplication | 1 | 2015 | 125 | 0.030 |
Why?
|
| Low Density Lipoprotein Receptor-Related Protein-5 | 1 | 2013 | 4 | 0.030 |
Why?
|
| Glucose Intolerance | 1 | 2014 | 96 | 0.030 |
Why?
|
| Cross-Over Studies | 1 | 2015 | 399 | 0.030 |
Why?
|
| Lipase | 1 | 2013 | 22 | 0.030 |
Why?
|
| N-Acetylgalactosaminyltransferases | 1 | 2013 | 12 | 0.030 |
Why?
|
| DNA Copy Number Variations | 1 | 2015 | 171 | 0.030 |
Why?
|
| Least-Squares Analysis | 1 | 2013 | 48 | 0.030 |
Why?
|
| Alpha-Ketoglutarate-Dependent Dioxygenase FTO | 1 | 2013 | 41 | 0.030 |
Why?
|
| Protein Kinase C-alpha | 1 | 2013 | 27 | 0.030 |
Why?
|
| Nedd4 Ubiquitin Protein Ligases | 1 | 2013 | 14 | 0.030 |
Why?
|
| Radioimmunoassay | 1 | 2013 | 155 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 2013 | 110 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 1 | 2015 | 927 | 0.030 |
Why?
|
| Pattern Recognition, Automated | 1 | 2014 | 217 | 0.030 |
Why?
|
| Estrogen Receptor alpha | 1 | 2013 | 144 | 0.030 |
Why?
|
| Receptors, Interleukin-18 | 1 | 2012 | 2 | 0.030 |
Why?
|
| Amino Acid Sequence | 1 | 2016 | 2062 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 16 | 1 | 2012 | 79 | 0.030 |
Why?
|
| Rats, Mutant Strains | 1 | 2012 | 23 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 2012 | 106 | 0.030 |
Why?
|
| Lipocalin-2 | 1 | 2012 | 38 | 0.030 |
Why?
|
| Interleukin-18 | 1 | 2012 | 26 | 0.030 |
Why?
|
| Lipocalins | 1 | 2012 | 35 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2013 | 369 | 0.030 |
Why?
|
| Acute-Phase Proteins | 1 | 2012 | 37 | 0.030 |
Why?
|
| Signal-To-Noise Ratio | 1 | 2012 | 96 | 0.030 |
Why?
|
| Oncogene Proteins | 1 | 2012 | 59 | 0.030 |
Why?
|
| Positron-Emission Tomography | 1 | 2013 | 329 | 0.030 |
Why?
|
| Lipoproteins, LDL | 1 | 2011 | 83 | 0.030 |
Why?
|
| Sample Size | 1 | 2012 | 130 | 0.030 |
Why?
|
| Aged, 80 and over | 2 | 2014 | 6509 | 0.030 |
Why?
|
| Receptors, Vasopressin | 1 | 2011 | 7 | 0.020 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2012 | 115 | 0.020 |
Why?
|
| Methylation | 1 | 2012 | 251 | 0.020 |
Why?
|
| North America | 1 | 2011 | 180 | 0.020 |
Why?
|
| Japan | 1 | 2011 | 307 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2016 | 2818 | 0.020 |
Why?
|
| Pulsatile Flow | 1 | 2010 | 49 | 0.020 |
Why?
|
| Cardiac-Gated Imaging Techniques | 1 | 2010 | 19 | 0.020 |
Why?
|
| Haplotypes | 1 | 2012 | 642 | 0.020 |
Why?
|
| Tissue Distribution | 1 | 2010 | 290 | 0.020 |
Why?
|
| Hyperuricemia | 1 | 2009 | 27 | 0.020 |
Why?
|
| Blood Flow Velocity | 1 | 2010 | 197 | 0.020 |
Why?
|
| Hypertriglyceridemia | 1 | 2009 | 67 | 0.020 |
Why?
|
| Databases as Topic | 1 | 2009 | 92 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2017 | 1920 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2012 | 1219 | 0.020 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2010 | 182 | 0.020 |
Why?
|
| Gadolinium DTPA | 1 | 2010 | 261 | 0.020 |
Why?
|
| Animals, Newborn | 1 | 2010 | 510 | 0.020 |
Why?
|
| Family Health | 1 | 2008 | 162 | 0.020 |
Why?
|
| Proteins | 1 | 2013 | 777 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2012 | 1540 | 0.020 |
Why?
|
| Coronary Artery Disease | 1 | 2012 | 350 | 0.020 |
Why?
|
| Alcohol Drinking | 1 | 2010 | 267 | 0.020 |
Why?
|
| Probability | 1 | 2008 | 355 | 0.020 |
Why?
|
| Hypertension, Renovascular | 1 | 2007 | 14 | 0.020 |
Why?
|
| Gene Deletion | 1 | 2008 | 329 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2012 | 1924 | 0.020 |
Why?
|
| Software | 1 | 2011 | 654 | 0.020 |
Why?
|
| Curriculum | 1 | 2011 | 539 | 0.020 |
Why?
|
| Incidental Findings | 1 | 2007 | 95 | 0.020 |
Why?
|
| WNK Lysine-Deficient Protein Kinase 1 | 1 | 2005 | 1 | 0.020 |
Why?
|
| Minor Histocompatibility Antigens | 1 | 2005 | 39 | 0.020 |
Why?
|
| Anthropometry | 1 | 2005 | 74 | 0.020 |
Why?
|
| Cytochrome P-450 CYP11B2 | 1 | 2005 | 3 | 0.020 |
Why?
|
| Physicians' Offices | 1 | 2005 | 3 | 0.020 |
Why?
|
| Rats | 1 | 2012 | 3990 | 0.020 |
Why?
|
| Genome | 1 | 2008 | 372 | 0.020 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2009 | 579 | 0.020 |
Why?
|
| Biological Transport | 1 | 2005 | 396 | 0.020 |
Why?
|
| Insulin | 1 | 2009 | 1160 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2006 | 912 | 0.010 |
Why?
|
| Atherosclerosis | 1 | 2007 | 244 | 0.010 |
Why?
|
| Nitric Oxide Synthase Type III | 1 | 2003 | 88 | 0.010 |
Why?
|
| Cholesterol | 1 | 2005 | 356 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2010 | 2232 | 0.010 |
Why?
|
| African Americans | 1 | 2002 | 10 | 0.010 |
Why?
|
| Cerebral Angiography | 1 | 2003 | 196 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 2002 | 307 | 0.010 |
Why?
|
| Diabetes Mellitus | 1 | 2009 | 806 | 0.010 |
Why?
|
| Hemodynamics | 1 | 2003 | 711 | 0.010 |
Why?
|
| Recurrence | 1 | 2003 | 1139 | 0.010 |
Why?
|
| Echocardiography | 1 | 2002 | 911 | 0.010 |
Why?
|